Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Marshfield Clinic

Neither a doctor nor a teaching hospital

Research payments

$1,795,261

879 payments

Through program year 2025, Marshfield Clinic is reported as receiving $1,795,261 in research payments, across 879 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $391,841 230
2024 Research $144,378 61
2023 Research $394,189 333
2022 Research $213,721 51
2021 Research $208,538 75
2020 Research $115,604 42
2019 Research $326,990 87

Breakdown

Who paid Research payments · program years 2019–2025
  1. Pfizer Inc. $322,134 155 payments
  2. Rhythm Pharmaceuticals, Inc. $321,554 211 payments
  3. Amgen Inc. $185,886 14 payments
  4. MorphoSys AG $161,885 9 payments
  5. Retrophin, Inc. $141,213 116 payments
  6. AbbVie, Inc. $131,491 31 payments
  7. Quidel Corporation $88,626 2 payments
  8. Novartis Pharmaceuticals Corporation $88,624 4 payments
  9. bioMerieux $51,288 36 payments
  10. Medtronic USA, Inc. $50,079 3 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3 Placebocontrolled Randomized Observerblinded Study to Evaluate the Efficacy Safety and Tolerability of A Clostridium Difficile Vaccine in Adults 50 Years of Age and Older $322,134 155 payments
  2. A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) $161,885 9 payments
  3. EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway $151,187 142 payments
  4. Ph3 Pediatric CM Study. $118,785 4 payments
  5. Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor $116,979 29 payments
  6. Long Term Extension Trial of Setmelanotide $106,363 7 payments
  7. Strep 98 $88,626 2 payments
  8. Open-Label Extension Study of Setmelanotide in Patients with a Rare Genetic, Syndromic or Acquired Disease of the MC4R Pathway $64,004 62 payments
  9. Sante $50,079 3 payments
  10. A randomized, multicenter, open-label trial comparing the effectiveness of an "inclisiran first" implementation strategy to usual care on LDL cholesterol (LDL-C) in patients with atherosclerotic cardiovascular disease and elevated LDL-C (70 mg/dL) despite receiving maximally tolerated statin therapy (VICTORION-INITIATE) $47,137 3 payments
What the money was spent on Research payments · program years 2019–2025
  1. Other $113,137 110 payments
  2. Patient care $10,472 2 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record